

## Publikationsliste Dr. med. Kathrin Niemöller

---

- 1: Ndrepepa G, Braun S, Mehilli J, **Niemöller K**, Schömig A, Kastrati A.  
A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol. 2007 Jan;96(1):30-7. Epub 2006 Oct 30. PubMed PMID: 17066344.
  
- 2: Ndrepepa G, Kastrati A, Braun S, Mehilli J, **Niemöller K**, von Beckerath N, von Beckerath O, Vogt W, Schömig A.  
N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am J Med. 2006 Apr;119(4):355.e1-8. PubMed PMID: 16564781.
  
- 3: Ndrepepa G, Braun S, **Niemöller K**, Mehilli J, von Beckerath N, von Beckerath O, Vogt W, Schömig A, Kastrati A.  
Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation. 2005 Oct 4;112(14):2102-7. Epub 2005 Sep 26. PubMed PMID: 16186420.
  
- 4: Zavrski I, Naujokat C, **Niemöller K**, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O.  
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol. 2003 Jul;129(7):383-91. Epub 2003 Jul 8. PubMed PMID: 12851815.
  
- 5: **Niemöller K**, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, Possinger K, Sezer O.  
Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol. 2003 Apr;129(4):234-8. Epub 2003 Apr 17. PubMed PMID: 12700896.
  
- 6: Sezer O, **Niemöller K**, Jakob C, Heider U.  
Angiogenesis in multiple myeloma. Leuk Res. 2002 Jul;26(7):701-2. PubMed PMID: 12008091.
  
- 7: Sezer O, **Niemöller K**, Jakob C, Zavrski I, Heider U, Eucker J, Kaufmann O, Possinger K.  
Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol. 2001 Oct;80(10):598-601. PubMed PMID: 11732871.

8: Sezer O, Jakob C, **Niemöller K**.

Angiogenesis in cancer. *J Clin Oncol*. 2001 Jul 1;19(13):3299-301. PubMed PMID: 11432903.

9: Sezer O, **Niemöller K**, Kaufmann O, Eucker J, Jakob C, Zavrski I, Possinger K.

Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. *Eur J Haematol*. 2001 Apr;66(4):238-44. PubMed PMID: 11380603.

10: Sezer O, Jakob C, Eucker J, **Niemöller K**, Gatz F, Wernecke K, Possinger K.

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. *Eur J Haematol*. 2001 Feb;66(2):83-8. PubMed PMID: 11168514.

11: Sezer O, **Niemöller K**, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K.

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. *Ann Hematol*. 2000 Oct;79(10):574-7. PubMed PMID: 11100749.

12: Sezer O, **Niemöller K**, Jakob C, Langelotz C, Eucker J, Possinger K.

Novel approaches to the treatment of primary amyloidosis. *Expert Opin Investig Drugs*. 2000 Oct;9(10):2343-50. Review. PubMed PMID: 11060811.